Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They currently have a $6.

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

H.C. Wainwright analyst Ed Arce affirms a Buy rating on shares of Inventiva (IVA) after the company announced the completion of patient ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.